Maze Therapeutics Inc
MAZE
查看详细走势图
30.380USD
-1.330-4.19%
收盘 03/27, 16:00（美东）报价延迟15分钟
1.33B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-4.19%
5天
-36.75%
1月
-33.36%
6月
+12.52%
今年开始到现在
-26.67%
1年
+169.57%
查看详细走势图
TradingKey Maze Therapeutics Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Maze Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名37/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价65.50。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Maze Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Maze Therapeutics Inc亮点
亮点风险
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
业绩转亏
公司业绩转亏，最新年度亏损美元
估值合理
公司最新PE估值-9.96，处于3年历史合理位
机构加仓
最新机构持股40.80M股，环比增加2.26%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值114.66K
分析师目标
根据
12
位分析师
买入
评级
65.500
目标均价
+33.67%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Maze Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Maze Therapeutics Inc简介
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
公司代码MAZE
公司Maze Therapeutics Inc
CEOColoma (Jason V)
网址https://www.mazetx.com/
相关品种
